Literature DB >> 29523398

Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy.

Christine Decanter1, Marc Cloquet2, Audrey Dassonneville2, Emmanuelle D'Orazio3, Audrey Mailliez4, Pascal Pigny5.   

Abstract

The relationship between early recovery of menstrual activity and blood anti-Müllerian hormone (AMH) concentrations were investigated within the first year post-chemotherapy in 32 young patients with breast cancer. All were treated by surgery and the same chemotherapy protocol (three cycles of FEC100 plus three cycles of taxanes). Menstrual activity, blood AMH (using picoAMH ELISA) and FSH concentrations were measured longitudinally before, during and up to 12 months after the end of chemotherapy (six samples per patient). Among the cohort, 17 patients recovered spontaneous cycles at +6 months (fast recovery) whereas the remaining 15 patients were still amenorrheic at that time (slow recovery). Blood AMH differed between these two subgroups at each time of the recovery phase starting at 3 months post-chemotherapy. The AMH patterns were also different: rapid and large increase in the fast recovery versus slow and partial increase in the slow recovery subgroup. No difference in ovarian recovery was observed between patients with a hormone positive or negative tumour. In conclusion, studying the post-chemotherapy patterns of menstrual activity and AMH, two paces of early ovarian recovery are distinguishable in young breast cancer patients who received the same chemotherapy protocol. This suggests different individual ovarian susceptibilities to chemotherapy.
Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMH; Amenorrhoea; Breast cancer; Chemotherapy; Follicle development

Mesh:

Substances:

Year:  2018        PMID: 29523398     DOI: 10.1016/j.rbmo.2018.02.004

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

1.  Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery.

Authors:  Hyun-Ah Kim; Jihye Choi; Chan Sub Park; Min-Ki Seong; Sungeun Hong; Jae-Sung Kim; In-Chul Park; Jin Kyung Lee; Woo Chul Noh
Journal:  Endocr Connect       Date:  2018-07-16       Impact factor: 3.335

2.  Ovarian reserve in premenopausal women with breast cancer.

Authors:  Xiangyun Zong; Yang Yu; Wenhu Chen; Weiwei Zong; Hongjian Yang; Xuan Chen
Journal:  Breast       Date:  2022-06-02       Impact factor: 4.254

3.  Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.

Authors:  Beth Zhou; Brian Kwan; Milli J Desai; Vinit Nalawade; Kathryn J Ruddy; Paul C Nathan; Henry J Henk; James D Murphy; Brian W Whitcomb; H Irene Su
Journal:  Fertil Steril       Date:  2022-02-23       Impact factor: 7.490

4.  A case report and follow-up of the first live birth after heterotopic transplantation of cryopreserved ovarian tissue in Eastern Europe.

Authors:  Triin Tammiste; Keiu Kask; Peeter Padrik; Külli Idla; Karin Rosenstein; Tatjana Jatsenko; Piret Veerus; Andres Salumets
Journal:  BMC Womens Health       Date:  2019-05-14       Impact factor: 2.809

5.  Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.

Authors:  Richard A Anderson; David Cameron; Florian Clatot; Isabelle Demeestere; Matteo Lambertini; Scott M Nelson; Fedro Peccatori
Journal:  Hum Reprod Update       Date:  2022-05-02       Impact factor: 17.179

6.  Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery

Authors:  Hyun-Ah Kim; Jihye Choi; Chan Su Park; Min-Ki Seong; Sung-Eun Hong; Jae-Sung Kim; In-Chul Park; Jin Kyung Lee; Woo Chul Noh
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

Review 7.  Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.

Authors:  Loes M E Moolhuijsen; Jenny A Visser
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.